Patents by Inventor Arvid Söderhäll

Arvid Söderhäll has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tetrahydrocarbazole derivatives having improved biological action and improved solubility as ligands of G-protein coupled receptors (GPCPs)
    Patent number: 8067456
    Abstract: The present invention provides novel tetrahydrocarbazole derivatives which have improved properties and which can be employed as inhibitors of GPCRs. This results in the possibility of using the novel compounds to treat pathological conditions whose severity depends on the pathobiochemical effect of GPCRs. The compounds of the invention act in particular via an antagonistic inhibition of the LHRH receptor. The invention further provides medicaments which comprise one or more of the novel compounds as active ingredient. The medicaments are suitable in particular to be employed in an oral dosage form for a mammal, in particular a human.
    Type: Grant
    Filed: February 14, 2008
    Date of Patent: November 29, 2011
    Assignee: AEterna Zentaris GmbH
    Inventors: Klaus Paulini, Matthias Gerlach, Eckhard Gunther, Emmanuel Polymeropoulos, Silke Baasner, Peter Schmidt, Ronald Kühne, Arvid Söderhäll
  • Tetrahydrocarbazole derivatives having improved biological action and improved solubility as ligands of G-protein coupled receptors (GPCRs)
    Patent number: 7375127
    Abstract: The present invention provides novel tetrahydrocarbazole derivatives which have improved properties and which can be employed as inhibitors of GPCRs. This results in the possibility of using the novel compounds to treat pathological conditions whose severity depends on the pathobiochemical effect of GPCRs. The compounds of the invention act in particular via an antagonistic inhibition of the LHRH receptor. The invention further provides medicaments which comprise one or more of the novel compounds as active ingredient. The medicaments are suitable in particular to be employed in an oral dosage form for a mammal, in particular a human.
    Type: Grant
    Filed: June 30, 2005
    Date of Patent: May 20, 2008
    Assignee: AE Zentaris GmbH
    Inventors: Klaus Paulini, Matthias Gerlach, Eckhard Günther, Emmanuel Polymeropoulos, Silke Baasner, Peter Schmidt, Ronald Kühne, Arvid Söderhäll